CRSP - CRISPR Therapeutics AG
| Previous Close | 41.82 |
| Open | 42.05 |
| Bid | 43.62 x 900 |
| Ask | 43.74 x 900 |
| Day's Range | 40.59 - 43.85 |
| 52 Week Range | 32.30 - 74.00 |
| Volume | 252,768 |
| Avg. Volume | 1,100,035 |
| Market Cap | 2.639B |
| Beta (5Y Monthly) | 2.72 |
| PE Ratio (TTM) | 37.07 |
| EPS (TTM) | 1.17 |
| Earnings Date | Apr 26, 2020 - Apr 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 74.46 |
- Insider Monkey
Hedge Funds Have Never Been This Bullish On CRISPR Therapeutics AG (CRSP)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Zacks
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.
- Zacks
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $44.67 in the latest trading session, marking a +0.84% move from the prior day.
- GlobeNewswire
CRISPR Therapeutics Proposes Changes to the Board of Directors
CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year. The Company also announced that Pablo Cagnoni, M.D., Chief Executive Officer of Rubius Therapeutics, will resign from the Board of Directors to focus on other commitments, effective immediately. “On behalf of our Board of Directors and management team, I would like to thank Pablo for his years of service and his many contributions to CRISPR Therapeutics, and I wish him the best in his future endeavors,” said Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics.
- American City Business Journals
Blood disorder startup files for $86M IPO
As competitors narrow in, a blood disorder-focused Cambridge startup is planning to raise more funds through an IPO.
- Benzinga
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
- Zacks
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $57.76 in the latest trading session, marking a +1.33% move from the prior day.
- GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+.
- Investor's Business Daily
CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS Rating
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Can it continue?
- Zacks
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.
- Zacks
Expand Your Portfolio with this First Profit Stock Screener
Expand Your Portfolio with this First Profit Stock Screener
- Zacks
CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.
- Zacks
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- TechCrunch
Mammoth Biosciences aims to be Illumina for the gene editing generation
In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20 years later, Mammoth Biosciences is hoping to do the same thing for gene editing tools. The company, co-founded by Jennifer Doudna, who did some of the pioneering work to discover the gene editing enzyme known as CRISPR, has just raised $45 million as it looks to bring to market products that can be used not only for disease detection, but are more precise editing tools for genetic material.
- Zacks
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
- American City Business Journals
Acceleron stock soars on lung drug trial data
Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.
- American City Business Journals
European ruling threatens Broad's CRISPR gene-editing patents
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
- Zacks
SCANS: The FAANG of The Roaring 20s
A new acronym of equities that could define the next decade of investing.
- Zacks
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
- GlobeNewswire
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
- Investor's Business Daily
These Top Fund Managers Outperform With Stocks That Many Other Investors Avoid
If you look for mutual funds to invest in, 2019 was a blast. The S&P; 500's 2019 gain of 31.49% was the broad market's best since 2013's 32.39%.
- Investor's Business Daily
Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
